more to follow
A very warm welcome to the November 2nd, 2014 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”.
EURETINA are delighted to continue our delivery of up to date summary briefs on a range of topics of interest to retinal specialists and researchers across Europe. This resource is designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.
Nicox S.A. (NYSE Euronext Paris: COX), a company focused on the ophthalmology medicines market has announced the approval by its shareholders for the acquisition of… Read More »Nicox SA completes purchase of Aciex Therapeutics, Inc. following shareholder approval of over 97%
A new Phase II clinical trial based in the US has been commenced to compare three separate doses of intravitreal ALG-1001 (“Luminate”) against bevacizumab or… Read More »Phase II study initiated with novel anti-integrin compound for the treatment of diabetic macular edema (DME)
Delegates to the 14th EURETINA Congress, held in London, UK from Sept 11th-14th, heard exciting developments across a range of innovative technologies short-listed for this… Read More »Winner of 2014 EURETINA Science & Medicine Innovation Awards highlights the progress of robotic precision in retinal surgery
In late 2012 research by an international consortium of scientists from Asia showed that three new genes appeared to associate with primary angle closure glaucoma… Read More »GWAS studies highlight three new genes linked to glaucoma, including PLEKHA7, a gene with a putative role in the barrier function of epithelial cells
pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a company based in Massachusetts, USA, has announced the receipt of approval from the FDA for its sustained release fluocinolone acetonide… Read More »pSivida Corporation receives $25M milestone payment from licensee Alimera Sciences Inc. following FDA approval of Iluvien
Researchers based at the Jules Stein Eye Institute Retina Division and David Geffen School of Medicine, University of California, Los Angeles, have published the results… Read More »Results of two open-label phase I/II studies of stem cell-derived RPE treatments for retinal degeneration are published in the Lancet
Research into direct-to-consumer (DTC) genetic tests, conducted at the Department of Ophthalmology, Erasmus Medical Center, Rotterdam, has concluded that while most of the commercial tests… Read More »Dutch study finds direct-to-consumer genetic testing for AMD not yet ready for clinical application
Ophthotech Corporation (Nasdaq:OPHT) has announced the triggering of a $50 million enrollment milestone payment from Novartis as part of a licensing and commercialization agreement focused… Read More »Ophthotech Corporation (Nasdaq:OPHT) receives $50M milestone payment from Novartis for clinical progression of Fovista